Zentalis Pharmaceuticals (ZNTL) FY 2025 Conference May 20, 2025 11:30 AM ET Speaker0 Great. I'd like to welcome everybody back to our morning session. I'd like to welcome everybody again to the H. C. Wainwright BioConnect Investor Conference at Nasdaq. Presenting, with us next is Zentalis Pharmaceuticals, and we have chief executive officer and president Julie Eastland, and we have Zentalis' CMO, Igmar Ber Burns Bruns. Welcome, and it's my pleasure to host you today. Speaker1 Thanks for having us as always ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charte ...

Exhibit 99.1 Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, Calif. — May 14, 2025 — Zentalis® Pharmaceuti ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially fir ...

As previously disclosed, the Company aligned with the U.S. Food and Drug Administration (FDA) on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial: Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinica ...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical data as of an ...

Exhibit 99.1 Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ TO _________ Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. (I.R.S. Employer Identification No.) 92121 (Zip Code) | | Securities regist ...

Core Insights - Zentalis Pharmaceuticals has reported positive clinical data for azenosertib, a WEE1 inhibitor, showing meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) [1][2] - The company anticipates topline data from the registration-intent DENALI Part 2 study by the end of 2026 [1][3] - Zentalis has strengthened its management team to support its focused strategy and has a cash position projected to last into late 2027 [1][2] Clinical Development - Updated clinical data from the DENALI Part 1b study showed an objective response rate (ORR) of 34.9% in patients with Cyclin E1+ PROC tumors, with a median duration of response (mDOR) of 6.3 months as of January 13, 2025 [3] - In the MAMMOTH study, Cyclin E1+ patients treated with azenosertib had an ORR of 31.3% and an mDOR of 4.2 months [3] - The ZN-c3-001 Phase 1 study reported an ORR of 34.8% and an mDOR of 5.2 months for patients treated with azenosertib [3] - The company has aligned with the FDA on the study design for DENALI Part 2, which will begin enrollment in the first half of 2025 [3] Financial Performance - As of December 31, 2024, Zentalis had cash, cash equivalents, and marketable securities totaling $371.1 million, sufficient to fund operations into late 2027 [1][5] - Research and development expenses for 2024 were $167.8 million, a decrease from $189.6 million in 2023, primarily due to reduced personnel expenses [5][12] - General and administrative expenses increased to $87.1 million in 2024 from $64.4 million in 2023, largely due to higher personnel costs [5][12] Corporate Updates - The company received Fast Track Designation from the FDA for azenosertib for treating PROC patients who are Cyclin E1 positive [4][6] - A strategic restructuring was announced in January 2025 to enhance efficiency in clinical development, which is expected to be completed by the second quarter of 2025 [4][6] - Zentalis has continued patient enrollment in various clinical trials, including studies for uterine serous carcinoma and in combination with bevacizumab [4][6]

Core Insights - Zentalis Pharmaceuticals is presenting four posters at the 2025 AACR Annual Meeting, focusing on the clinical efficacy and broad therapeutic applications of azenosertib, a WEE1 inhibitor for high-grade serous ovarian cancer [1][2][5] Group 1: Azenosertib Overview - Azenosertib is a novel, selective, and orally bioavailable WEE1 inhibitor currently being evaluated in clinical studies for ovarian cancer and other tumor types [3][5] - The mechanism of action involves inhibiting WEE1, which allows cell cycle progression despite DNA damage, leading to cancer cell death [3] Group 2: Clinical Research and Presentations - The poster titled "Loss of RB1 sensitizes TP53-mutated cancer cells to WEE1 inhibition by azenosertib" will be presented on April 27, 2024 [2] - Another poster, "Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib," is scheduled for April 28, 2024 [2] - Azenosertib's potential as a potent and selective WEE1 kinase inhibitor with broad antitumor activity will be highlighted on April 29, 2024 [2] - The final poster presentation will discuss the synergistic anti-tumor activity of azenosertib in combination with encorafenib and cetuximab on April 29, 2024 [2] Group 3: Company Background - Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib for patients with Cyclin E1+ platinum-resistant ovarian cancer [5] - The company is leveraging its expertise to explore additional therapeutic opportunities for azenosertib beyond its current indications [5]